卵巢癌患者的生育力保存
Fertility Preservation in Patients with Ovarian Cancer
DOI: 10.12677/acm.2024.1441082, PDF,   
作者: 丁金钰：青岛市黄岛区人民医院产科，山东 青岛；徐艳斐：青岛市黄岛区第二中医医院妇产科，山东 青岛
关键词: 卵巢癌；治疗；DNA损伤；生育力保存；Ovarian Cancer； Treatment； DNA Damage； Fertility Preservation
摘要: 随着诊断技术的进步和治疗手段的提高，卵巢癌患者幸存比例明显增加，但在癌症治疗过程中，手术及某些放化疗手段均会对卵巢功能造成不可逆转的损伤，随着卵巢癌患者生存时间的延长和生存率的提高，很多患者不得不面临生育力折损的严重问题，但人们目前对生育力保存时机、适用方法及存在的风险认识尚浅，本文结合最近研究进展，对临床常用的卵巢癌治疗手段对女性生育力产生的损伤及目前适用于卵巢癌女性的生育力保存方法进行了总结，希望能够为临床上卵巢癌患者的诊疗及生育力保存提供依据。
Abstract: With the advancement of diagnostic technology and improvement in treatment methods, there has been a significant increase in the survival rate of ovarian cancer patients. However, in the course of cancer treatment, certain surgical procedures, as well as radiotherapy and chemotherapy treatments, can lead to irreversible damage to ovarian function. As the survival time extends and the overall survival rate improves for ovarian cancer patients, many individuals are confronted with the serious issue of fertility loss. Unfortunately, there is still limited awareness regarding the optimal timing, suitable methods, and associated risks of fertility preservation. This review summarized recent research progress on the detrimental effects on female fertility caused by commonly used clinical treatments for ovarian cancer and present current applicable fertility preservation methods for women with this condition. We hope to provide a basis for clinical management and fertility preservation in patients with ovarian cancer.
文章引用：丁金钰, 徐艳斐. 卵巢癌患者的生育力保存[J]. 临床医学进展, 2024, 14(4): 724-730. https://doi.org/10.12677/acm.2024.1441082

参考文献

[1] American Cancer Society (2023) Cancer Facts & Figures 2023. Atlanta.
https://www.cancer.org/cancer/types/ovarian-cancer.html
[2] World Health Organization (WHO) (2020) Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019.
https://www.who.int/data/global-health-estimates
[3] Cho, K.R. and Shih, I.M. (2009) Ovarian Cancer. Annual Review of Pathology: Mechanisms of Disease, 4, 287-313. [Google Scholar] [CrossRef] [PubMed]
[4] Taylan, E. and Oktay, K. (2019) Fertility Preservation in Gynecologic Cancers. Gynecologic Oncology, 155, 522-529. [Google Scholar] [CrossRef] [PubMed]
[5] Rives, N., Courbière, B., Almont, T., Kassab, D., Berger, C., Grynberg, M., Papaxanthos, A., Decanter, C., Elefant, E., Dhedin, N., Barraud-Lange, V., Béranger, M.C., Demoor-Goldschmidt, C., FrédéRique, N., Bergère, M., Gabrel, L., Duperray, M., Vermel, C., Hoog-Labouret, N., Pibarot, M., Provansal, M., Quéro, L., Lejeune, H., Methorst, C., Saias, J., Véronique-Baudin, J., Giscard D’Estaing, S., Farsi, F., Poirot, C. and Huyghe, É. (2022) What Should Be Done in Terms of Fertility Preservation for Patients with Cancer? The French 2021 Guidelines. European Journal of Cancer, 173, 146-166. [Google Scholar] [CrossRef] [PubMed]
[6] Chelariu-Raicu, A., Cobb, L.P. and Gershenson, D.M. (2021) Fertility Preservation in Rare Ovarian Tumors. International Journal of Gynecologic Cancer, 31, 432-441. [Google Scholar] [CrossRef] [PubMed]
[7] 曹冬焱. 卵巢癌规范化诊疗与进展[J]. 中国临床医生杂志, 2023, 51(3): 268-271.
[8] Kuroki, L. and Guntupalli, S.R. (2020) Treatment of Epithelial Ovarian Cancer. BMJ, 371, m3773. [Google Scholar] [CrossRef] [PubMed]
[9] Reynolds, A.C. and McKenzie, L.J. (2023) Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options. Journal of Clinical Oncology, 41, 2281-2292. [Google Scholar] [CrossRef] 
[10] Gershenson, D.M. (2017) Management of Borderline Ovarian Tumours. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 49-59. [Google Scholar] [CrossRef] [PubMed]
[11] 中国优生科学协会肿瘤生殖学分会中国医师协会微无创医学专业委员会妇科肿瘤学组中国医师协会整合医学分会妇产疾病整合专业委员会. 交界性卵巢肿瘤诊治中国专家共识(2022年版) [J]. 中国实用妇科与产科杂志, 2022, 38(12): 1185-1194.
[12] Crafton, S.M., Cohn, D.E., Llamocca, E.N., Louden, E., Rhoades, J. and Felix, A.S. (2020) Fertility-Sparing Surgery and Survival among Reproductive-Age Women with Epithelial Ovarian Cancer in 2 Cancer Registries. Cancer, 126, 1217-1224. [Google Scholar] [CrossRef] [PubMed]
[13] Nasioudis, D., Chapman-Davis, E., Frey, M.K., Witkin, S.S. and Holcomb, K. (2017) Could Fertility-Sparing Surgery Be Considered for Women with Early Stage Ovarian Clear Cell Carcinoma? Journal of Gynecologic Oncology, 28, e71. [Google Scholar] [CrossRef] [PubMed]
[14] Wallace, W.H., Thomson, A.B. and Kelsey, T.W. (2003) The Radiosensitivity of the Human Oocyte. Human Reproduction, 18, 117-121. [Google Scholar] [CrossRef] [PubMed]
[15] Blackford, A.N. and Jackson, S.P. (2017) ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Molecular Cell, 66, 801-817. [Google Scholar] [CrossRef] [PubMed]
[16] Turgeon, M.O., Perry, N.J.S. and Poulogiannis, G. (2018) DNA Damage, Repair, and Cancer Metabolism. Frontiers in Oncology, 8, Article 15. [Google Scholar] [CrossRef] [PubMed]
[17] Sancar, A., Lindsey-Boltz, L.A., Unsal-Kaçmaz, K. and Linn, S. (2004) Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints. Annual Review of Biochemistry, 73, 39-85. [Google Scholar] [CrossRef] [PubMed]
[18] Adriaens, I., Smitz, J. and Jacquet, P. (2009) The Current Knowledge on Radiosensitivity of Ovarian Follicle Development Stages. Human Reproduction Update, 15, 359-377. [Google Scholar] [CrossRef] [PubMed]
[19] Baker, T.G. (1971) Radiosensitivity of Mammalian Oocytes with Particular Reference to the Human Female. American Journal of Obstetrics and Gynecology, 110, 746-761. [Google Scholar] [CrossRef] [PubMed]
[20] Taylan, E. and Oktay, K.H. (2017) Current State and Controversies in Fertility Preservation in Women with Breast Cancer. World Journal of Clinical Oncology, 8, 241-248. [Google Scholar] [CrossRef] [PubMed]
[21] Zhu, F., Gao, J., Zeng, F., Lai, Y., Ruan, X. and Deng, G. (2022) Hyperoside Protects against Cyclophosphamide Induced Ovarian Damage and Reduced Fertility by Suppressing HIF-1α/BNIP3-Mediated Autophagy. Biomedicine & Pharmacotherapy, 156, Article ID: 113743. [Google Scholar] [CrossRef] [PubMed]
[22] Zoń, A. and Bednarek, I. (2023) Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions. International Journal of Molecular Sciences, 24, Article 7585. [Google Scholar] [CrossRef] [PubMed]
[23] Brozovic, A., Ambriović-Ristov, A. and Osmak, M. (2010) The Relationship between Cisplatin-Induced Reactive Oxygen Species, Glutathione, and BCL-2 and Resistance to Cisplatin. Critical Reviews in Toxicology, 40, 347-359. [Google Scholar] [CrossRef] [PubMed]
[24] Srinivas, U.S., Tan, B.W.Q., Vellayappan, B.A. and Jeyasekharan, A.D. (2019) ROS and the DNA Damage Response in Cancer. Redox Biology, 25, Article ID: 101084. [Google Scholar] [CrossRef] [PubMed]
[25] Kashi, O., Roness, H., Spector, I., Derech-Haim, S. and Meirow, D. (2023) Dual Suppression of Follicle Activation Pathways Completely Prevents the Cyclophosphamide-Induced Loss of Ovarian Reserve. Human Reproduction, 38, 1086-1098. [Google Scholar] [CrossRef] [PubMed]
[26] Jang, H., Lee, O.H., Lee, Y., Yoon, H., Chang, E.M., Park, M., Lee, J.W., Hong, K., Kim, J.O., Kim, N.K., Ko, J.J., Lee, D.R., Yoon, T.K., Lee, W.S. and Choi, Y. (2016) Melatonin Prevents Cisplatin-Induced Primordial Follicle Loss via Suppression of PTEN/AKT/FOXO3a Pathway Activation in the Mouse Ovary. Journal of Pineal Research, 60, 336-347. [Google Scholar] [CrossRef] [PubMed]
[27] Chang, E.M., Lim, E., Yoon, S., Jeong, K., Bae, S., Lee, D.R., Yoon, T.K., Choi, Y. and Lee, W.S. (2015) Cisplatin Induces Overactivation of the Dormant Primordial Follicle Through PTEN/AKT/FOXO3a Pathway Which Leads to Loss of Ovarian Reserve in Mice. PLOS ONE, 10, e0144245. [Google Scholar] [CrossRef] [PubMed]
[28] Senra, J.C., Roque, M., Talim, M.C.T., Reis, F.M. and Tavares, R.L.C. (2018) Gonadotropin-Releasing Hormone Agonists for Ovarian Protection during Cancer Chemotherapy: Systematic Review and Meta-Analysis. Ultrasound in Obstetrics & Gynecology, 51, 77-86. [Google Scholar] [CrossRef] [PubMed]
[29] Bai, F., Lu, Y., Wu, K., Chen, Q., Ding, L., Ge, M. and Weng, Z. (2017) Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis. Breast Care, 12, 48-52. [Google Scholar] [CrossRef] [PubMed]
[30] Lambertini, M., Horicks, F., Del Mastro, L., Partridge, A.H. and Demeestere, I. (2019) Ovarian Protection with Gonadotropin-Releasing Hormone Agonists during Chemotherapy in Cancer Patients: From Biological Evidence to Clinical Application. Cancer Treatment Reviews, 72, 65-77. [Google Scholar] [CrossRef] [PubMed]
[31] Pinelli, S. and Basile, S. (2018) Fertility Preservation: Current and Future Perspectives for Oncologic Patients at Risk for Iatrogenic Premature Ovarian Insufficiency. BioMed Research International, 2018, Article ID: 6465903. [Google Scholar] [CrossRef] [PubMed]
[32] Harada, M. and Osuga, Y. (2019) Fertility Preservation for Female Cancer Patients. International Journal of Clinical Oncology, 24, 28-33. [Google Scholar] [CrossRef] [PubMed]
[33] Chung, K., Donnez, J., Ginsburg, E. and Meirow, D. (2013) Emergency IVF versus Ovarian Tissue Cryopreservation: Decision Making in Fertility Preservation for Female Cancer Patients. Fertility and Sterility, 99, 1534-1542. [Google Scholar] [CrossRef] [PubMed]
[34] Oktay, K., Buyuk, E., Libertella, N., Akar, M. and Rosenwaks, Z. (2005) Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation with Tamoxifen and Letrozole for Embryo Cryopreservation. Journal of Clinical Oncology, 23, 4347-4353. [Google Scholar] [CrossRef] 
[35] Sönmezer, M., Türkçüoğlu, I., Coşkun, U. and Oktay, K. (2011) Random-Start Controlled Ovarian Hyperstimulation for Emergency Fertility Preservation in Letrozole Cycles. Fertility and Sterility, 95, 2125.E9-2125.E11. [Google Scholar] [CrossRef] [PubMed]
[36] Grynberg, M., Raad, J., Comtet, M., Vinolas, C., Cédrin-Durnerin, I. and Sonigo, C. (2018) Fertility Preservation in BRCA-Mutated Women: When and How? Future Oncology, 14, 483-490. [Google Scholar] [CrossRef] [PubMed]
[37] Hoskins, P.J. and Gotlieb, W.H. (2017) Missed Therapeutic and Prevention Opportunities in Women with BRCA-Mutated Epithelial Ovarian Cancer and Their Families Due to Low Referral Rates for Genetic Counseling and BRCA Testing: A Review of the Literature. CA: A Cancer Journal for Clinicians, 67, 493-506. [Google Scholar] [CrossRef] [PubMed]
[38] Grynberg, M., Dagher Hayeck, B., Papanikolaou, E.G., Sifer, C., Sermondade, N. and Sonigo, C. (2019) BRCA1/2 Gene Mutations Do Not Affect the Capacity of Oocytes from Breast Cancer Candidates for Fertility Preservation to Mature in Vitro. Human Reproduction, 34, 374-379. [Google Scholar] [CrossRef] [PubMed]
[39] Lambertini, M., Goldrat, O., Ferreira, A.R., Dechene, J., Azim Jr., H.A., Desir, J., Delbaere, A., T’Kint De Roodenbeke, M.D., De Azambuja, E., Ignatiadis, M. and Demeestere, I. (2018) Reproductive Potential and Performance of Fertility Preservation Strategies in BRCA-Mutated Breast Cancer Patients. Annals of Oncology, 29, 237-243. [Google Scholar] [CrossRef] [PubMed]
[40] 李小兰, 张志强, 梁晓燕. 遗传性妇科肿瘤人群生育力的保存[J]. 实用妇产科杂志, 2023, 39(1): 15-18.
[41] Medrano, J.V., Andrés, M.D.M., García, S., Herraiz, S., Vilanova-Pérez, T., Goossens, E. and Pellicer, A. (2018) Basic and Clinical Approaches for Fertility Preservation and Restoration in Cancer Patients. Trends in Biotechnology, 36, 199-215. [Google Scholar] [CrossRef] [PubMed]
[42] Wallace, W.H., Kelsey, T.W. and Anderson, R.A. (2016) Fertility Preservation in Pre-Pubertal Girls with Cancer: The Role of Ovarian Tissue Cryopreservation. Fertility and Sterility, 105, 6-12. [Google Scholar] [CrossRef] [PubMed]
[43] Harada, M. and Osuga, Y. (2016) Where Are Oncofertility and Fertility Preservation Treatments Heading in 2016? Future Oncology, 12, 2313-2321. [Google Scholar] [CrossRef] [PubMed]
[44] Santos, M.L., Pais, A.S. and Almeida Santos, T. (2021) Fertility Preservation in Ovarian Cancer Patients. Gynecological Endocrinology, 37, 483-489. [Google Scholar] [CrossRef] [PubMed]

为你推荐